Mianserin
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Mianserin: From Depression to Benign Paroxysmal Torticollis of Infancy
One-Sentence Summary
Mianserin is a tetracyclic antidepressant, referenced in the evidence pack’s own literature as an established treatment for depression. The TxGNN model’s top-ranked prediction is Benign Paroxysmal Torticollis of Infancy, but this pairing is currently supported by no clinical trials and no published literature — the score reflects the model’s internal ranking only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Depression (tetracyclic antidepressant; inferred from supporting literature in this pack — no formal regulatory indication text available) |
| Predicted New Indication | Benign Paroxysmal Torticollis of Infancy |
| TxGNN Prediction Score | 99.49% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Mianserin is not currently available (flagged as a High-severity data gap, DG002). Based on the literature retrieved for related predictions in this pack, Mianserin is a tetracyclic antidepressant with established efficacy in depressive disorders, and is pharmacologically related to noradrenergic/serotonergic-modulating agents such as mirtazapine.
For this specific top-ranked prediction — Benign Paroxysmal Torticollis of Infancy, a self-limiting paediatric episodic vestibular/migraine-related movement disorder — no mechanistic rationale, clinical trial, or literature evidence is currently available to support a plausible biological link to an antidepressant’s known pharmacology. This prediction should be treated as a model-generated hypothesis only, not as evidence of clinical relevance.
By contrast, several lower-ranked predictions in this same evidence pack (dysthymic disorder, agoraphobia, neurotic disorder) are supported by multiple published studies and are pharmacologically coherent with Mianserin’s antidepressant/anxiolytic profile — see Conclusion and Next Steps below.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No UK marketing authorisation is currently on record for Mianserin (market status: Not marketed; 0 licences registered in the source dataset).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: TFDA label warnings/contraindications are flagged as a Blocking data gap (DG001) — this must be resolved before any S1 safety assessment can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Benign Paroxysmal Torticollis of Infancy) has a high TxGNN score but zero supporting clinical trials or literature, and no established mechanistic link to Mianserin’s known pharmacology. Evidence is insufficient to proceed.
To proceed, the following is needed:
- Mechanism of action data for Mianserin (DrugBank API query — DG002)
- TFDA/MHRA label warnings and contraindications (DG001, Blocking — required before any safety review)
- Preclinical or clinical evidence specifically linking Mianserin to this paediatric condition
- Formal original indication/regulatory documentation for Mianserin
Alternative candidates worth prioritising: Within this same evidence pack, dysthymic disorder, agoraphobia, and neurotic disorder (ranks 2, 3, 7) are supported by multiple published studies and greater pharmacological plausibility given Mianserin’s antidepressant class. These may warrant evaluation ahead of the top-ranked but evidence-free prediction above.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.